Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO

The candidate vaccine developed by the Oxford University and the Serum Institute of India is among the two such vaccines added to the ongoing Ebola clinical trials, according to a World Health Organisation (WHO) statement, making it the first addition of candidate vaccines to the trials specifically targeting the Bundibugyo virus that has caused the current Ebola outbreak in the Democratic…

Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO

We haven't written up this one. Hindustan Times has the full story — the link below goes straight to it.

Read the original at hindustantimes.com →

More in Health & Medicine

Daewoong Pharmaceutical Reports Promising Phase 1 Results for Autoimmune Drug Candidate Plodicitinib

Daewoong Pharmaceutical is advancing the development of its next-generation autoimmune disease treatment candidate, Plodicitinib, following encouraging interim results from its Phase 1 clinical…

  • Daewoong Pharmaceutical reports positive Phase 1 results for Plodicitinib
  • Study involved 44 healthy adults with high immune protein occupancy
  • Plodicitinib targets JAK3, ITK, and BTK to treat autoimmune diseases

More from Tuesday 17 November →